Thromboxane A 2 (TXA 2 ) induces platelet adhesion through thromboxane prostanoid (TP) receptor. Platelets contain many pro-angiogenic factors and are recruited to the site of vascular injury. However, the cellular and molecular mechanisms of platelet-dependent angiogenesis, especially the involvement of TP signalling, have not been fully elucidated. The present study hypothesized that TP-dependent platelet adhesion would contribute to angiogenesis in a mouse hindlimb ischaemic model.
Introduction
Angiogenesis, a phenomenon involving the formation of new vessels from the pre-existing microvasculature, is an essential component of recovery from ischaemic conditions. 1 Platelets are critical to haemostasis and subsequent angiogenesis in wound healing, and transfusion of platelets enhances the angiogenic recovery of blood flow in models of ischaemia. 2 -5 In the meantime, depletion of platelets suppresses blood flow recovery. 6, 7 Platelets are a major source of angiogenic growth factors, including VEGF, stromal cell-derived factor-1 (SDF-1), PDGF, and FGF-2, as well as other factors that play a role in angiogenesis. 8 -10 After activation, platelets release various anti-and pro-angiogenic factors, the latter of which include VEGF, SDF-1, PDGF, and others. 11, 12 Recent reports described that the mononuclear cells recruited from bone marrow (BM) have a pro-angiogenic potential, and in fact, mononuclear cells injected to the ischaemic sites enhance the recovery from ischaemia. 13 Furthermore, it has been
shown that the release of the CXC chemokine, SDF-1, and VEGF from activated platelets enhanced the recruitment of BM-derived, CXCR4 + VEGFR-1 + cells, 14, 15 which in turn accelerate neovascularization and tumour metastasis formation. 16 These findings suggest that the activated platelets play a critical role in the process of angiogenesis through the secretion of pro-angiogenic growth factors and the mobilization of BM-derived progenitor cells.
Furthermore, to exhibit the pro-angiogenic activity, platelets interact with microvascular ECs. It has been reported that the interactions between platelets and ECs are mediated by various adhesion molecules. In particular, P-selectin glycoprotein ligand-1 (PSGL-1) is an important cellular adhesion molecule that is expressed on the EC surface, especially in the ischaemic or damaged endothelium, and P-selectin has been suggested to participate in post-ischaemic angiogenesis; 17 however, the initiation of these interactions is not fully elucidated. Thromboxane A 2 (TXA 2 ) is a potent stimulator of platelet activation, aggregation, and vascular constriction. It exerts its biological activity by binding to a G-protein-coupled specific receptor, the thromboxane prostanoid (TP) receptor. TXA 2 is generated and participates in pathological conditions such as ischaemia, inflammation, and atherosclerosis through interactions with microvascular ECs. 18 -20 TXA 2 may act as a potent angiogenic stimulator directly as well as indirectly by supplying cytokines such as pro-angiogenic factors upon platelet aggregation. 21 -23 Moreover, TXA 2 may enhance angiogenesis by enhancing the interactions between platelets and ECs. However, the role of TP signalling in platelets in angiogenesis in vivo remains to be elucidated. In the present study, we determined whether or not TP signalling enhances angiogenesis in acute ischaemic hind limb model via enhancement of interaction of platelets with endothelial cells (ECs). Additionally, we evaluated the mechanisms by which TP signalling facilitates ischaemia-induced angiogenesis.
Methods
Detailed methods are available in Supplementary material online.
Animals and surgery
The study was performed in accordance with the guidelines for animal experiments at the Kitasato University School of Medicine. Male 8-week-old C57Bl/6 mice were obtained from Crea Japan (Tokyo, Japan). TP knockout mice (TP 2/2 ), PGI 2 receptor knockout mice (IP 2/2 ), and VEGFR1-tyrosine kinase knockout mice (VEGFR1-TK 2/2 ), all with a C57Bl/6 hybrid background, were developed for this study. 23, 24 The model of hindlimb ischaemia has been described previously. 6, 14, 25 Mice were anaesthetized by an intraperitoneal injection of ketamine (5 mg/kg body weight) and xylazine (100 mg/kg body weight) throughout the experiments, and its adequacy was monitored from the disappearance of the pedal withdrawal reflex.
In vivo microscopy
At 7 postsurgical days, the animals were anaesthetized by an intraperitoneal injection of pentobarbital sodium (50 mg/kg) and were prepared for in vivo fluorescence microscopy according to modifications of previously described methods. 26 
Blood platelets
The number of platelets was measured with a Celltac automatic cell counter (MEK-6450, Nihon Kohden, Japan).
Flow cytometric analysis
Blood was drawn via the tail vein 1 day after surgery. The white blood cell (WBC) fraction, including platelets, was obtained by Ficoll separation and flow cytometric analysis was performed as described previously. 27 2.5 Plasma and platelet-rich plasma levels of VEGF and SDF-1
Plasma and platelet-rich plasma (PRP) levels of VEGF and SDF-1 were assessed by murine-specific ELISA (R&D Systems, Minneapolis, MN, USA).
Quantitative real-time PCR
Transcripts encoding VEGFR-1, -2, -3, CXCR4, PSGL-1, P-selectin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were quantified by real-time RT-PCR analysis as described previously.
Bone marrow transplantation
BM transplantation was performed as reported previously. 28 
Immunofluorescence
IF staining was performed as described previously.
Statistical analysis
Data are expressed as the means + S.D. All statistical analyses were performed using the GraphPad Prism version 5.01 (GraphPad Software, La Jolla, CA, USA). Statistical comparison between two groups was performed using the Student's t-test. Comparisons more than two groups were analysed using one-way ANOVA. Comparisons between the time point effects were analysed by repeated-measures ANOVA. If applicable with a repeated-measure approach, Bonferroni post hoc test was performed.
A P-value of ,0.05 was considered statistically significant.
Results

Reduced blood flow recovery from ischaemia in TP knockout mice
To determine whether TXA 2 enhances angiogenesis, the role played by endogenous TXA 2 in blood flow recovery in the hindlimb ischaemic model was investigated. Whereas blood flow recovery was restored at 28 days after ligation in mice treated with PBS, treatment with the TXA 2 receptor antagonist S-1452 or with the TXA 2 synthase inhibitor OKY-046 significantly delayed blood flow recovery ( Figure 1A ) and reduced microvascular density (MVD) compared with vehicle-treated mice ( Figure 1B and C ). PGI 2 and TXA 2 are major prostanoids in the cardiovascular system. Those opposite actions on vasculature and platelets are well known, and their balance is critical in various vascular diseases such as vascular occlusive diseases and coronary heart disease. Among WT, TP 2/2 , and IP 2/2 , there are no significant changes in platelet counts and the number of megakaryocytes in BM (see Supplementary material online, Figure S1A -C). But, TP 2/2 significantly prolonged bleeding time compared with WT. In contrast, IP 2/2 significantly shortened bleeding time (see Supplementary material online, Figure S1D ). PGI 2 has effect on platelet activity inhibition. It was reported that IP 2/2 do not develop spontaneous thrombosis, but are more susceptible to thrombotic stimuli than their WT littermates. If TP-mediated platelet aggregation helps to enhance ischaemia-induced angiogenesis, then IP signalling should counteract the process during an angiogenic response. IP 2/2 were subjected to acute hindlimb ischaemia to test this hypothesis. Figure 2A -D depicts the blood flow recovery from ischaemia as assessed by the flow ratio between the ischaemic limb and the untreated control limb. The lack of TP signalling resulted in delayed blood flow recovery and suppressed angiogenesis, as measured by the MVD. Importantly, IP 2/2 showed enhanced angiogenesis (0.86 + 0.08) and TP
2/2
showed reduced angiogenesis (0.45 + 0.098) compared with WT (0.67 + 0.12; n ¼ 6, P , 0.05; Figure 2A -D). These results suggested that TP signalling played a critical role in ischaemia-induced angiogenesis and that IP signalling counteracted the TP signalling.
Transplantation of WT BM cells into TP 2/2 mice enhances recovery from ischaemia
The recruitment of progenitor cells from BM plays a crucial role in ischaemic revascularization.
14,15 Figure 2E showed that blood flow recovery from ischaemia was enhanced in TP Figure 2F ). These results indicated that the recruitment of TP-expression BM cells contributed to recovery from ischaemia.
Heterogeneity of TP signalling-dependent platelet adhesion to ECs
We observed that TP signalling played a crucial role in revascularization in the ischaemic hindlimb model (Figures 1 and 2 ). This finding may implicate the involvement of activated platelet-endothelial interactions in angiogenic development in this model because TP signalling activates TP signalling and angiogenesis platelets in an autocrine or paracrine fashion. Mentioned above, the numbers of platelets and megakaryocytes present in the BM at 28 days after ischaemic induction were similar among TP 2/2 , IP 2/2 , and WT; the bleeding time in TP 2/2 was prolonged compared with that in IP 2/2 and WT (see Supplementary material online, Figure S1D ).
To clarify whether TP-activated platelet-EC interactions were responsible for angiogenesis, platelet adhesion to the microvessel endothelium in ischaemic tissues was examined by in vivo microscopy. Whereas no adherent platelets were seen in microvessels in nonischaemic tissues from TP 2/2 , WT, and IP 2/2 ( Figure 3A) , adherent platelets were visible as fluorescent dots along the surface of the ECs in the ischaemic tissue of WT mice ( Figure 3B ). Intravital microscopy revealed that the platelets were bound directly to the ECs, rather than indirectly bound via adherent leucocytes. The number of microvessels with walls stained with rhodamine 6G was greater in WT and IP 2/2 than in TP
( Figure 3B) . Furthermore, quantitative analysis on day 7 revealed that the platelet-adherent microvascular density in the vasculature of perifemoral and muscle sites was suppressed in TP 2/2 compared with WT ( Figure 3C ). To estimate whether platelets bound to ECs, IF analysis against endothelial CD31 and aIIb, stained specific against platelets, was performed. CD31-positive ECs also stained against aIIb in WT and IP 2/2 but rarely seen in TP 2/2 ( Figure 3D ). Moreover, platelet adhered to the vascular lumen in WT and IP 2/2 but not in TP 2/2 ( Figure 3E ). These results indicated that TP signalling facilitated selective platelet adhesion to the microvessels at the angiogenic sites, suggesting that the heterogeneity of TP signalling-dependent platelet adhesion to ECs is a key event in angiogenic enhancement.
Involvement of P-selectin in platelet -EC interactions in neovascularized sites and its regulation by TP signalling
To determine whether altered platelet functions during acute hindlimb ischaemia would affect the ischaemia-induced microvascular response, including platelet adhesion to microvessels, the platelet counts and activation status were determined in mice. There was no significant difference in platelet counts throughout the experimental period, with the exception of the first day after ligation ( Figure 4A ).
However, flow cytometry analysis revealed that the population of P-selectin + CD41 + platelets in TP 2/2 at 7 days after hindlimb ischaemia (0.20 + 0.05) was smaller than that in WT (0.75 + 0.25; n ¼ 5, P , 0.05; Figure 4B ). The machinery involved in platelet adhesion to ECs in the neovasculature was analysed by treating mice with neutralizing antibodies against the adhesion molecules. P-selectin mediates platelet adhesion to the endothelium via PSGL-1. IF analysis against endothelial CD31 and P-selectin revealed that P-selectin was stained around ECs in WT and Figure 4C ). This result supported that P-selectin induced by TP signalling mediates platelet adhesion to ECs. To determine whether P-selectin induced platelet adhesion after femoral artery ligation, mice were injected with P-selectin neutralizing antibody. Antibody-treated mice showed marked suppression of platelet adhesion compared with untreated mice ( Figure 4D vs. 3B) . Quantitative analysis on day 7 revealed that the platelet-adherent microvascular density in the vasculature of perifemoral and muscle sites was dramatically diminished in WT and IP 2/2 but not in TP 2/2 ( Figure 4E ). Figure 4F ). We observed no evidence for a large thrombus that could have blocked blood flow at the angiogenic sites. Those results suggested that the ischaemia-induced platelet -endothelial interaction was mediated by P-selectin, and that TP signalling facilitated this mechanistic pathway.
TP-dependent PSGL-1 up-regulation in neovascularized ECs acts as a determinant of EC heterogeneity
The mRNA levels of PSGL-1 were measured to confirm whether PSGL-1 contributed to blood flow recovery and found to be reduced in TP 2/2 after ligation ( Figure 5A ). To prove that platelet-derived P-selectin bound to PSGL-1 on ECs, immunohistochemical analysis against PSGL-1 and endothelial CD31 was performed. Before induction of the ischaemic condition, ECs that were positive for PSGL-1 and endothelial CD31 were not seen. However, the numbers of PSGL-1/endothelial CD31-double-positive ECs were increased substantially in WT and IP 2/2 at 7 days after ligation compared with TP 2/2 ( Figure 5B ).
Triple IF staining of P-selectin/PSGL-1/CD31 showed that plateletderived P-selectin bound to PSGL-1-positive ECs in WT and IP
2/2
but rarely seen in TP 2/2 mice ( Figure 5C ). Treatment with U-46619, a thromboxane analogue, increased but not significantly the expression of PSGL-1 on HUVECs compared with control ( Figure 5D ). Exposed to cobalt chloride (CoCl 2 ), to mimic hypoxia condition, significantly induces expression of PSGL-1 on HUVECs ( Figure 5E ). Furthermore, treatment with combination of U-46619 and CoCl 2 induces two-fold expression of PSGL-1 compared with control ( Figure 5F ). In contrast, the expression of P-selectin on HUVECs was significantly suppressed compared with control ( Figure 5G ). These results suggested that hypoxic conditions enhanced the effect of TP signalling on PSGL-1 expression on endothelium compared with normoxic conditions and enhanced the expression of PSGL-1 on endothelium cause heterogeneity of angiogenic endothelial cells at angiogenic sites, and that indicated P-selectin expressed on platelets could bind to PSGL-1 on EC.
Roles of VEGF and SDF-1 in TP-dependent revascularization
On the basis of our previous observation that activated platelets release pro-angiogenic growth factors, including VEGF and SDF-1, 14 we assessed the plasma levels of VEGF ( Figure 6A ) and SDF-1 ( Figure 6B 1.165 + 0.06 ng/mL). To clarify the functional relevance of VEGF and SDF-1 in ischaemic revascularization, mice were treated with neutralizing antibodies against VEGF and CXCR4 (a receptor for SDF-1). The VEGF and CXCR4 antibodies suppressed blood flow recovery in WT and IP 2/2 but not in TP 2/2 at day 28 ( Figure 6C and D) . These results suggested that TP signalling was important for ischaemia-induced angiogenesis through its involvement in the production of VEGF and SDF-1.
VEGF and SDF-1 are released from platelet interaction with EC
Treatment with P-selectin antibody suppressed platelet-deposited microvascular density and blood flow recovery in WT ( Figure 4E ), suggesting that angiogenesis can be attributed to P-selectin-mediated interaction between platelets and ECs. To further examine whether platelets release VEGF and SDF-1 after femoral artery ligation, we measured the levels of VEGF and SDF-1 in PRP from mice treated with P-selectin antibody or IgG. There was no significant change in the level of VEGF and SDF-1 in PRP concentration treatment with P-selectin antibody and control IgG in WT and TP 2/2 mice before femoral artery ligation (see Supplementary material online, Figure S2A and B). But on day 1 after femoral artery ligation ( Figure 6E and F ) , the levels of VEGF in PRP from WT treated with P-selectin antibody (102.3 + 6.5 pg/mL) were significantly decreased, compared with IgG (202.5 + 32.7 pg/mL); in TP 2/2 , however, there was no difference in VEGF levels between P-selectin antibody and IgG: P-selectin antibody: 99.8 + 6.8 pg/mL; IgG: 102.6 + 6.5 pg/mL (P ¼ 0.689; Figure 6E ). Levels of SDF-1 in PRP from WT treated with P-selectin antibody (1.37 + 0.15 ng/mL) were significantly decreased, compared with IgG (2.07 + 0.06 ng/mL); in TP 2/2 mice, however, there was no difference in SDF-1 levels in PRP between treatments: P-selectin antibody, 1.28 + 0.25 ng/mL; IgG, 1.42 + 0.21 ng/mL (P ¼ 0.188; Figure 6F ). These results suggested that activated platelets release VEGF and SDF-1 and enhance angiogenesis, which is dependent on TXA 2 -TP signalling.
Identification of VEGF receptor subtypes involved in ischaemia-induced revascularization
VEGF interacts with VEGFR-1, -2, and -3 on the cellular membrane. Of these VEGF receptor subtypes, the first two are reportedly active in the enhancement of angiogenesis. To examine whether VEGFR-1 and -2 contribute to blood flow recovery from ischaemic conditions, acute hindlimb ischaemia was induced in VEGFR-1 TK 2/2 and WT treated with the VEGFR-2 tyrosine kinase inhibitor ZD6474. Treatment with ZD6474 did not affect the blood flow recovery from ischaemia in WT compared with treatment with vehicle (IgG 0.68 + 0.05, ZD6474 0.63 + 0.92, n ¼ 5, P ¼ 0.43; Figure 7A ). In contrast, blood flow recovery was impaired in VEGFR-1 TK 2/2 compared with WT (VEGFR-1 TK 2/2 0.43 + 0.06, WT 0.62 + 0.08; P , 0.002; Figure 7B ). These results indicated that VEGFR-1 was the predominant receptor involved in facilitating blood flow recovery and angiogenesis during acute hindlimb ischaemia. Moreover, the mRNA levels of VEGFR-1 and -2, but not VEGFR-3, were reduced in TP 2/2 mice at day 7 ( Figure 7C ). Because SDF-1 levels were also elevated after acute hindlimb ischaemia, we measured the mRNA level of CXCR4 in ischaemic muscles. Figure 7D shows that the CXCR4 mRNA level was attenuated in TP 2/2 compared with WT at 7 days after induction of ischaemia.
3.9 TP-dependent mobilization of
cells in ischaemic muscle
During recovering from myelosuppression, metalloproteinae-9 (MMP-9) is essential for the recruitment of other stem cells that express Stem cell factor (SCF). 29 MMP-9 and SCF support mobilization and recruitment of haematopoietic progenitor cell. 29 After femoral artery ligation, plasma levels of pro-MMP-9 and SCF were significantly decreased in TP 2/2 compared with WT (see Supplementary material online, Figure   S3A and B). We also confirmed reconstitution of haematopietic cell by irradiation to WT and TP 2/2 . Supplementary material online, Figure   S4A and B showed that the recovery of WBCs and platelet counts after irradiation were significantly delayed in TP 2/2 compared with WT. In addition, plasma level of SCF and BM level of pro-MMP-9 were also significantly suppressed in TP 2/2 (see Supplementary material online, Figures S1 and 6C and D) . These results suggested that TP signalling is important for recovery from myelosuppression and mobilization of haematopoietic stem cell. We previously reported that the mobilization of CXCR4 18.0 + 4.12, IP 60.5 + 9.98, P , 0.05; Figure 7G and H ). These findings suggested that TP signalling promotes the mobilization of CXCR4 1 -VEGFR1 1 cells to ischaemic muscle. 
Discussion
In the present study, endogenous TXA 2 promoted ischaemia-induced angiogenesis through P-selectin-mediated selective platelet adhesion to PSGL-1-expressing ECs in ischaemic hindlimb tissues. Increased SDF-1 and VEGF levels facilitated angiogenesis, with the recruitment of BM-derived pro-angiogenic cells expressing CXCR4 + VEGFR1 + to the ischaemic tissues. These results suggest that platelet adhesion plays a critical role in angiogenesis in ischaemic tissue. They also implicate the heterogeneity of TP signalling-dependent platelet adhesion to PSGL-1 on ECs, which is involved in the mobilization of CXCR4 + VEGFR1 + cells, as a key event in angiogenesis.
In addition to their function in haemostasis, platelets play important roles in wound healing and tumour growth. 30, 31 As an arachidonic acid metabolite, TXA 2 is one of the most potent endogenous factors involved in platelet stimulation. In human but not mouse platelets, TP exists as two isoforms, TPa and TPb. TPa activates, but TPb inhibits, adenylatecyclase. 32 Taken together, TPa and TPb interact to coordinate platelet activation. Ashton et al. 33, 34 reported that a TXA 2 agonist antagonized the pro-angiogenic effects in TPb transgenic mice. Including the present report, almost all of the related studies have used models lacking TPb expression. In addition to inducing thrombus formation, TXA 2 is also a potent arteriole constrictor, restricting blood supply to tissues. Consequently, the actions of TXA 2 reduce the regional blood flow and may blunt ischaemic recovery. The reverse is also true, as indicated in the present study. Microvascular ECs display extensive functional heterogeneity, depending on their location in the vascular tree. 35, 36 The existence of organ-and microvascular-bed-specific ECs, and even intravascular variations in EC gene expression, emphasizes their high cell-to-cell variability and adaptability to changing conditions. The ability of microvascular ECs to respond dynamically to pathology-related microenvironmental changes is particularly apparent in angiogenesis. We observed that the heterogeneity of ECs in terms of platelet adhesion strongly depended on TP signalling ( Figure 3) . The IP signalling demonstrated to have a potent inhibitory effect on platelet activation. Conversely, IP 2/2 displayed increased platelet activity and angiogenesis (Figures 1-3) . The TP-dependent adhesion initiated the mechanistic pathway for enhancing the angiogenic response to ischaemia. To clarify the machinery of platelet adhesion to angiogenic ECs, a neutralizing antibody against P-selectin was tested ( Figure 4) . P-selectin (CD62P) is of interest because of its role in modulating interactions between blood cells and the endothelium, and also because of the possible use of its soluble form as a plasma predictor of adverse cardiovascular events. Indeed, a greater percentage of P-selectin-positive platelets was observed during ischaemia-induced angiogenic responses, which suggested that the ischaemia-exposed platelets might have been activated. This finding also implied that, in addition to its release from the a-granules and dense granule membranes of platelets, soluble P-selectin might have been released from the Weibel-Palade bodies of the ECs. Increased P-selectin expression on activated platelets is believed to induce platelet adhesion to ECs, possibly through binding to PSGL-1. Infusion of activated platelet P-selectin also rapidly stimulated WeibelPalade body release in a previous study, as indicated by elevated plasma von Willebrand factor levels and an increase in endothelial P-selectin expression. 37 Our intravital microscopic approach allowed us to observe the interactions between platelets and ECs in vivo. P-selectin-mediated platelet adhesion occurred selectively in angiogenic ECs, and the number of platelets that expressed P-selectin was significantly decreased in TP 2/2 .
The P-selectin antibody did not appear to suppress platelet adhesion in TP 2/2 , which indicated that the initial step in the P-selectin-mediated platelet/endothelium interaction was TP-dependent. Immunostaining at the angiogenic sites was performed to confirm PSGL-1 expression on the ECs after femoral artery ligation. In WT, the expression of PSGL-1 in ischaemic muscle was up-regulated compared with TP 2/2 . Furthermore, triple IF staining revealed that platelets-derived P-selectin bound to PSGL-1-expressing CD31-positive ECs in ischaemic muscle from WT and IP 2/2 but rarely seen from TP 2/2 ( Figure 5C ). Treatment with CoCl 2 activated PSGL-1 expression on HUVECs, which was further strengthened by combination treatment with U-44619 and CoCl 2 . These results indicated that TP signalling enhanced the expression of PSGL-1 on ECs under the hypoxic condition, which may have resulted in the heterogeneous angiogenicity of the ECs. These findings suggested that the heterogeneous nature of the EC angiogenicity in terms of platelet adhesion might be explained by the P-selectin/PSGL-1 machinery. It was previously reported that endothelium-adherent platelets could initiate monocyte recruitment to ECs. 38 Rolling is mediated by P-selectin on activated platelets and PSGL-1-constitutively expressed on monocytes. 39 42 Furthermore, a recent study suggested that activated P-selectin-expressing platelets drive the recruitment of PSGL-1-expressing neutrophils to the inflamed venules to initiate inflammation. 43 Therefore, it also remains to be clarified whether the interaction of platelets with CXCR4 + VEGFR1 + cells indeed contributes to promote tissue repair and recovery from ischaemia. Pro-angiogenic growth factors are crucial for the evolution of angiogenesis in response to hindlimb ischaemia. 14, 15 The present and several previous studies 14, 44 have confirmed that VEGF and SDF-1 protein and mRNA levels are increased in the hindlimb ischaemic model. We also established that a neutralizing antibody against VEGF or CXCR4 suppressed the angiogenic response to ischaemia in WT and IP 2/2 but not in TP 2/2 . Recent evidence has indicated that platelets release VEGF and SDF-1 after cytokine-induced activation in vitro and in vivo during vascular injury. 14, 45 The present study also showed that TXA 2 -TP signalling enhanced angiogenesis and platelet adhesion to ischaemia-exposed ECs, accompanied by reductions in the PRP levels of VEGF and SDF-1 treated with P-selectin antibody. These results suggested that platelets adhere to neovascularized microvessels during ischaemia in a TXA 2 -TP-dependent manner, and that the adherent platelets mediate pro-angiogenic responses by supplying VEGF and SDF-1 to the sites of angiogenesis. In thrombocytopenic mice, the elevation of plasma levels of SDF-1 is severely impaired, as are the mobilization of pro-angiogenic CXCR4 + VEGFR1 + cells and tissue revascularization. However, the restoration of platelet production or enforced SDF-1 expression can restore neoangiogenesis, which provides evidence for the essential role of platelet-derived SDF-1 in regulating neovascularization.
14 Although the present study indicates that TP signalling promotes ischaemia-induced angiogenesis via P-selectin-mediated platelet adhesion to PSGL-1-expressing ECs at ischaemic sites, it remains unknown whether overexpressing TP receptors in platelets would facilitate revascularization after hindlimb ischaemia without any adverse effects. We also need further studies to confirm the importance of P-selection on activated platelets and of PSGL-1 on the ischaemic ECs in acceleration of angiogenesis in vivo.
The activated platelets secreting haematopoietic cytokines, including VEGF and SDF-1, thereby may stimulate the recruitment of CXCR4 + VEGFR1 + cells to restore blood flow from ischaemia and to promote angiogenesis. The heterogeneity of TP signalling-dependent platelet adhesion to PSGL-1-expressing ECs in the ischaemic regions is a key event in the enhancement of neovascularization. TP signallingdependent angiogenic machinery may be a good target for ischaemiainduced revascularization in vivo.
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